Evogene Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Evogene şirketinin yıllık kazanç ve gelirinin sırasıyla 29.7% ve 43.4% oranında artması bekleniyor.

Anahtar bilgiler

29.7%

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi	49.6%
Gelir büyüme oranı	43.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	25 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

TASE:EVGN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	26	-18	N/A	N/A	2
12/31/2025	15	-22	N/A	N/A	2
12/31/2024	11	-23	N/A	N/A	2
9/30/2024	7	-24	-21	-20	N/A
6/30/2024	9	-20	-20	-20	N/A
3/31/2024	9	-21	-20	-19	N/A
12/31/2023	6	-24	-22	-22	N/A
9/30/2023	6	-20	-19	-18	N/A
6/30/2023	2	-23	-22	-21	N/A
3/31/2023	2	-25	-23	-22	N/A
12/31/2022	2	-27	-25	-24	N/A
9/30/2022	1	-31	-31	-30	N/A
6/30/2022	1	-32	-29	-28	N/A
3/31/2022	1	-29	-29	-28	N/A
12/31/2021	1	-28	-26	-25	N/A
9/30/2021	1	-29	-24	-24	N/A
6/30/2021	1	-26	-23	-22	N/A
3/31/2021	1	-24	-19	-19	N/A
12/31/2020	1	-23	-20	-20	N/A
9/30/2020	1	-21	-18	-17	N/A
6/30/2020	1	-21	-18	-17	N/A
3/31/2020	0	-21	-19	-18	N/A
12/31/2019	1	-18	-19	-18	N/A
9/30/2019	1	-18	-16	-16	N/A
6/30/2019	2	-18	-16	-16	N/A
3/31/2019	2	-19	-16	-16	N/A
12/31/2018	2	-21	-16	-15	N/A
9/30/2018	2	-21	-16	-16	N/A
6/30/2018	2	-21	N/A	-15	N/A
3/31/2018	3	-21	N/A	-16	N/A
12/31/2017	3	-21	N/A	-16	N/A
9/30/2017	4	-21	N/A	-17	N/A
6/30/2017	5	-21	N/A	-16	N/A
3/31/2017	5	-21	N/A	-15	N/A
12/31/2016	7	-20	N/A	-12	N/A
9/30/2016	8	-18	N/A	-12	N/A
6/30/2016	9	-17	N/A	-11	N/A
3/31/2016	10	-17	N/A	-12	N/A
12/31/2015	11	-17	N/A	-12	N/A
9/30/2015	12	-17	N/A	-10	N/A
6/30/2015	12	-17	N/A	-9	N/A
3/31/2015	13	-16	N/A	-8	N/A
12/31/2014	15	-15	N/A	-9	N/A
9/30/2014	17	-14	N/A	-8	N/A
6/30/2014	18	-12	N/A	-7	N/A
3/31/2014	18	-11	N/A	-6	N/A
12/31/2013	15	-9	N/A	-5	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EVGN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: EVGN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: EVGN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: EVGN şirketinin gelirinin (yıllık 43.4% ) IL pazarından (yıllık 1.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EVGN şirketinin gelirinin (yıllık 43.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EVGN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Evogene Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024

Evogene Ltd. Announces Executive Changes

Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024

Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Full year 2023 earnings released: US$0.52 loss per share (vs US$0.65 loss in FY 2022)

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.081 loss per share (vs US$0.16 loss in 3Q 2022)

Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2022)

Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

New minor risk - Share price stability

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Full year 2022 earnings released: US$0.65 loss per share (vs US$0.69 loss in FY 2021)

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.19 loss in 3Q 2021)

Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022

Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2021)

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 1Q 2021)

Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022

High number of new directors

Evogene Ltd. Announces Executive Changes

Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)

Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation

Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)

Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day high: ₪25.00

Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth

New 90-day high: ₪19.10

New 90-day high: ₪14.94

What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?

Third quarter 2020 earnings released: US$0.18 loss per share

Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020

First half earnings released

New 90-day high - ₪9.46

New 90-day high - ₪5.63

New 90-day high - ₪4.17

First half earnings released

Evogene Ltd. to Report Q2, 2020 Results on Aug 05, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin